Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TAS-1440 by Taiho Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
TAS-1440 is under clinical development by Taiho Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...